Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-17
DOI
10.3389/fphar.2021.589273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Autophagy Triggered by Oxidative Stress Appears to Be Mediated by the AKT/mTOR Signaling Pathway in the Liver of Sleep-Deprived Rats
- (2020) Yongmei Li et al. Oxidative Medicine and Cellular Longevity
- IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease
- (2020) Zheng Xiao et al. LIFE SCIENCES
- Dapagliflozin: A Review in Type 2 Diabetes
- (2019) Sohita Dhillon DRUGS
- Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet‐induced metabolic dysfunction and nonalcoholic fatty liver disease in mice
- (2019) Hao Chiang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1
- (2019) Yujun Tang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
- (2018) David Højland Ipsen et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus
- (2018) Noboru Kurinami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway
- (2018) Yao Lu et al. HEPATOLOGY
- Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
- (2018) Leigh Goedeke et al. HEPATOLOGY
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
- (2017) Kosuke Kaji et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
- (2017) Arun Chaudhury et al. Frontiers in Endocrinology
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Function of Autophagy in Nonalcoholic Fatty Liver Disease
- (2016) Mark J. Czaja DIGESTIVE DISEASES AND SCIENCES
- Nonalcoholic Fatty Liver Disease
- (2016) Fernando Bril et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism
- (2016) Anila K. Madiraju et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Experimental Diabetes Mellitus in Different Animal Models
- (2016) Amin Al-awar et al. Journal of Diabetes Research
- mTOR: a pharmacologic target for autophagy regulation
- (2015) Young Chul Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- AMPK and autophagy in glucose/glycogen metabolism
- (2015) Joohun Ha et al. MOLECULAR ASPECTS OF MEDICINE
- Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies
- (2014) Hwan-Woo Park et al. Autophagy
- α-lipoic acid reduces fatty acid esterification and lipogenesis in adipocytes from overweight/obese subjects
- (2014) Marta Fernández-Galilea et al. Obesity
- Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks
- (2011) S. Alers et al. MOLECULAR AND CELLULAR BIOLOGY
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
- (2011) Joungmok Kim et al. NATURE CELL BIOLOGY
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Lampe1: An ENU-Germline Mutation Causing Spontaneous Hepatosteatosis Identified through Targeted Exon-Enrichment and Next-Generation Sequencing
- (2011) Rachel Sheridan et al. PLoS One
- Autophagy in nonalcoholic steatohepatitis
- (2011) Muhammad Amir et al. Expert Review of Gastroenterology & Hepatology
- AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-β Peptide Metabolism
- (2010) Valérie Vingtdeux et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search